Back

VICTORION-Difference study: Inclisiran-based strategy vs standard of care

30 August 2025 (17:00 - 17:10)
Organised by: Logo
Congress Presentation Part of: HOT LINE 4 Lipid-Lowering Agents ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Professor Ulf Landmesser

Charite University Hospital, Berlin (Germany)

11 More presentations in this session

Presentation thumbnail
BaxHTN – Efficacy and safety of the aldosterone synthase inhibitor baxdrostat in patients with uncontrolled or resistant hypertension
Professor B. Williams (London, GB)
Slides Video
Presentation thumbnail
Discussant review - BaxHTN
Professor T. Guzik (Edinburgh, GB)
Slides Video
Presentation thumbnail
Panel discussion - BaxHTN
Presentation thumbnail
KARDIA-3: Zilebesiran as Add-on Therapy in Adults with Hypertension and Established Cardiovascular Disease or at High Cardiovascular Risk
Doctor N. Pagidipati (Durham, US)
Slides Video
Presentation thumbnail
Discussant review - KARDIA-3
Professor M. Tomaszewski (Manchester, GB)
Slides Video

Access the full session

Session thumbnail
HOT LINE 4
Video

The Event

Event poster

ESC Congress 2025

30 August 2025 17:00 CET
You may be interested in
thumbnail
Congress Presentation
Low-density lipoprotein cholesterol goal attainment with "inclisiran first" versus usual care in patients with atherosclerotic cardiovascular disease
thumbnail
Congress Presentation
Lipid goal attainment across baseline socioeconomic and clinical factors comparing an "inclisiran first" implementation strategy and usual care: subgroup analysis of VICTORION-INITIATE
thumbnail
Congress Presentation
VICTORION IMPLEMENT: an observational study of the lipid management landscape in Germany

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources